The call emphasized strong operational momentum: record quarterly sales, robust U.S. growth (27% YoY; 40% CAGR over six halves), high procedure volumes (~17,000 last 12 months; ~180,000 total), industry-leading sales productivity (~$2M per rep) and improving operating cash flow (positive in December). At the same time, management flagged meaningful risks and constraints: small current market share (~3.9%), geographic volatility (notably China), dependence on the U.S., the need to carefully pace sales rep expansion to protect revenue per rep, working capital unpredictability, and a broad guidance range. On balance the call projects positive execution and growth momentum but acknowledges operational and market-access risks that could impact near-term predictability.

Company Guidance

Management reiterated that it remains on track to deliver its guidance (noting it is a deliberately broad range) and to deliver improving operating performance and cash flow—highlighting positive operating cash flow and higher cash in December despite a significant working‑capital build; key metrics cited include LTM sales growth of ~24% (3x industry), U.S. LTM growth ~27%, a U.S. CAGR of ~40% over the last six halves, six consecutive halves of growth with January momentum continuing, a current run‑rate of ~17,000 procedures in the last 12 months (180,000 procedures used historically), an estimated ~3.9% share of the MIGS market, sales per rep of nearly $2.0M, a stable unit price of ~USD1,000, and the broader market context of ~84M glaucoma patients, ~$4.3B in topical drug spend, 32M annual cataract procedures and ~1 in 5 cataract patients also having glaucoma.

Strong Revenue Growth and Record Quarter

Record sales in the December quarter; last 12 months sales up ~24% year-over-year overall, with management reporting continuing momentum into January.

Robust U.S. Performance and High CAGR

United States revenue growth of ~27% over the last 12 months and a reported 40% compound annual growth rate (CAGR) in the U.S. over the last six halves.

Procedure Volume and Market Traction

Run rate of ~17,000 procedures in the last 12 months and ~180,000 iTrack procedures performed globally to date, indicating sustained clinical adoption.

High Sales Productivity

Sales productivity reported as nearly $2.0 million revenue per sales rep in the last quarter, described as industry-leading and a key driver of operating results.

Regulatory Approvals, Reimbursement and Clinical Evidence

Device is FDA-approved and reimbursed by U.S. Centers for Medicare & Medicaid Services; management emphasized robust registry/real-world clinical evidence with a first peer-reviewed registry paper expected imminently.

Improving Operating Cash Flow and Operational Capacity

Management reported positive operating cash flow in the December quarter and a month-over-month cash increase in December; capacity to scale production from an FDA-approved Fremont factory; improvement in cost of goods sold with volume.

Nova Eye Medical (AU:EYE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AU:EYE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 27, 2026	2026 (Q4)	- / -	-0.013	―	―	―
Feb 25, 2026	2026 (Q2)	>-0.01 / -0.01	-0.024	50.00% (+0.01)	―	―
Aug 27, 2025	2025 (Q4)	- / -0.01	-0.014	7.14% (<+0.01)	―	―
Feb 25, 2025	2025 (Q2)	>-0.01 / -0.02	-0.03	20.00% (<+0.01)	―	―
Aug 25, 2024	2024 (Q4)	- / -0.01	-0.051	72.55% (+0.04)	―	―
Feb 22, 2024	2024 (Q2)	- / -0.03	-0.044	31.82% (+0.01)	―	―
Aug 27, 2023	2023 (Q4)	- / -0.05	-0.03	-70.00% (-0.02)	―	―
Feb 28, 2023	2023 (Q2)	- / -0.04	-0.021	-109.52% (-0.02)	―	―
Aug 26, 2022	2022 (Q4)	- / -0.03	-0.019	-57.89% (-0.01)	―	―
Feb 16, 2022	2022 (Q2)	- / -0.02	-0.011	-90.91% (-0.01)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AU:EYE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 25, 2026	AU$0.16	AU$0.15	-3.13%
Aug 27, 2025	AU$0.14	AU$0.14	0.00%
Feb 25, 2025	AU$0.12	AU$0.12	-4.17%
Feb 22, 2024	AU$0.20	AU$0.20	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nova Eye Medical (AU:EYE) report earnings?

Nova Eye Medical (AU:EYE) is schdueled to report earning on Aug 27, 2026, TBA (Confirmed).

What is Nova Eye Medical (AU:EYE) earnings time?

Nova Eye Medical (AU:EYE) earnings time is at Aug 27, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Nova Eye Medical stock?

The P/E ratio of Nova Eye Medical is N/A.

What is AU:EYE EPS forecast?

Currently, no data Available